Clin Osteol 2015; 20(1): 21-28

Bone metabolism disorders in liver and gastrointestinal diseasesReview articles

T. Koller, J. Kollerová, J. Payer

Normal functioning of the digestive tract and the liver is important for normal bone metabolism. Patients with chronic cholestasis in primary biliary cirrhosis or primary sclerosing cholangitis and those with cirrhosis are most commonly affected by metabolic bone disease. Among gastrointestinal diseases, disorders of bone metabolism are found in celiac disease, ulcerative colitis, Crohn's disease, chronic pancreatitis, and in conditions following gastrectomy. Knowledge and anticipation of disorders of bone metabolism allow ear­ ly initiation of preventive measures and early diagnosis of severe bone metabolism disorders. Patients who are candidates for liver transplantation are the most vulnerable group. Osteoporotic fractures occurring after liver transplantation are so common that they need to be actively diagnosed and treated. Recommendations for the screening of bone metabolism disorders in at-risk patients with liver and digestive diseases are currently available. First, it is necessary to treat the underlying disease of the gastrointestinal tract and liver, and to supplement calcium and vitamin D. These measures often lead to improvements in bone mineral density. In severe cases, specific therapy for the treatment of osteoporosis is necessary.

Keywords: osteoporosis, secondary osteoporosis, celiac disease, inflammatory bowel disease, cirrhosis, primary biliary cirrhosis, chronic pancreatitis, gastrectomy

Published: June 11, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koller T, Kollerová J, Payer J. Bone metabolism disorders in liver and gastrointestinal diseases. Osteologický bulletin. 2015;20(1):21-28.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Payer J, Killinger Z a kolektív. Osteoporóza, Herba, s. r. o., Bratislava 2012.
    2. Rodes J, Benhamou JP, Blei A, Reichen J, Rizzetto M eds. Textbook Of Hepato­ logy, 3. vydanie, Blackwell Publishing Ltd., Oxford 2007. Go to original source...
    3. Leslie WD, Bernstein CN, Leboff MS. American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic dis­ orders. Gastroenterology 2003;3:941-966. Go to original source...
    4. Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver di­ sease. Clin Liver Dis 2005;4:747-766. Go to original source...
    5. Alcalde Vargas A, Pascasio Acevedo JM, Gutiérrez Domingo I, García Jiménez R, Sousa Martín JM, Ferrer Ríos MT, Sayago Mota M, Giráldez Gallego A, Gómez Bravo MA. Prevalence and Characteristics of Bone Disease in Cirrhotic Patients Under Evaluation for Liver Transplantation. Transplantation Proceedings 2012; 6:1496-1498. Go to original source...
    6. Poupon R. Ursodeoxycholic Acid and Bile-acid Mimetics as Therapeutic Agents for Cholestatic Liver Diseases: An Overview of Their Mechanisms of Action. Clinics and Research in Hepatology and Gastroenterology 2012;S1:S3-12. Go to original source...
    7. Collier J. Bone disorders in chronic liver disease. Hepatology 2007;4:1271-1278. Go to original source...
    8. Guanabens N, Monegal A, Cerdá D, Muxí A, Gifre L, Peris P, Prés A: A rando­ mized trial comparing monthly ibandronate and weekly alendronate for osteopo­ rosis in patients with primary biliary cirrhosis. Hepatology 2013;58:2070-2078. Go to original source...
    9. Rudic JS, Giljaca V, Krstic MN, Bjelakovic G, Gluud C. Bisphosphonates for osteoporosis in primary biliary cirrhosis. Cochrane Database Syst Rev 2011;12: CD009144. Go to original source...
    10. Pereira SP, O'Donohue J, Moniz C, Phillips MG, Abraha H, Buxton-Thomas M, Williams R. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther 2004;5:563-570. Go to original source...
    11. Parés A, Guanabens N. Treatment of bone disorders in liver disease. J Hepatol 2006;3:445-453. Go to original source...
    12. Tignor AS, Wu BU, Whitlock TL, Lopez R, Repas K, Banks PA, Conwell D. High prevalence of low-trauma fracture in chronic pancreatitis. Am J Gastroenterol 2010;12:2680-2686. Go to original source...
    13. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodés J, Munoz-Gómez J. Osteoporosis and Bone Mineral Metabolism Disorders in Cirrhotic Patients Referred for Orthotopic Liver Transplantation. Calcified Tissue International 1997;2:148-154. Go to original source...
    14. Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003;4: 321-330. Go to original source...
    15. Páv I. Celiakia v ambulantnej praxi. Via pract 2006;1:22-24.
    16. Rios LP, Khan A, Sultan M, McAssey K, Fouda MA, Armstrong D. Approach to diagnosing celiac disease in patients with low bone mineral density or fragility fractures: multidisciplinary task force report. Can Fam Physician 2013;10: 1055-1061.
    17. Szymczak J, Bohdanowicz-Pawlak A, Waszczuk E, Jakubowska J. Low bone mi­ neral density in adult patients with celiac disease. Endokrynol Pol 2012;4: 270-276.
    18. Lucendo AJ, García-Manzanares A Bone mineral density in adult coeliac disea­ se: An updated review. Rev Esp Enferm Dig 2013;3:154-162. Go to original source...
    19. Katz S, Weinerman S. Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (NY) 2010;8:506-517.
    20. Dítě P. Chronická pankreatitida. Galen 2002, první vydání.
    21. Payer J, Killinger Z, Aleryany S, Kratochvíl'ová M, Ondrejka P. Vitamin D defi­ ciency as one of the causes of bone changes in chronic pancreatitis. Vnitr Lek 1999;5:281-283.
    22. Duggan SN, Smyth ND, Murphy A, Macnaughton D, O'Keefe SJ, Conlon KC. High Prevalence of Osteoporosis in Patients with Chronic Pancreatitis: a Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2014;2: 219-228. Go to original source...
    23. Dujsikova H, Dite P, Tomandl J, Sevcikova A, Precechtelova M. Occurrence of metabolic osteopathy in patients with chronic pancreatitis. Pncreatology 2008;6:583-586. Go to original source...
    24. Bang UC, Benfield T, Bendtsen F, Hyldstrup L, Beck Jensen JE. The Risk of Fractures Among Patients With Cirrhosis or Chronic Pncreatitis. Clin Gastro­ enterol Hepatol 2014;2:320-326. Go to original source...
    25. Lark RK, Lester GE, Ontjes DA, Blackwood AD, Hollis BW, Hensler MM, Aris RM. Diminished and Erratic Absorption of Ergocalciferol in Adult Cystic Fibrosis Patients. The American Journal of Clinical Nutrition 2001;3:602-606. Go to original source...
    26. Aris RM, Lester GE, Renner JB, Winders A, Denene Blackwood A, Lark RK, Ontjes DA Efficacy of pamidronate for osteoporosis in patients with cystic fibro­ sis following lung transplantation. Am J Respir Crit Care Med 2000;162:941-946. Go to original source...
    27. Aris RM, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, Hecker TM, Renner JB, Guillen U, Brown SA, Neuringer IP, Chalermskulrat W, Ontjes DA Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004;1:77-82. Go to original source...
    28. Forsmark CE. Management of chronic pancreatitis. Gastroenterology 2013;6: 1282-1291. Go to original source...
    29. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;3:795-841. Go to original source...
    30. Kim HJ, Hong SJ, Jeon YW, Han JP, Han SH, Kang JH, Tae JW, Lim HS, Kim HK, Ko BM, Lee MS. The early onset of disease may be a risk factor for decrea­ sed bone mineral density in patients with inflammatory bowel disease. Clin Endosc 2013;1:71-76. Go to original source...
    31. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;2:176-181. Go to original source...
    32. Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of antiTNF-alpha therapy on spinal bone mineral density in patients with Crohn's disea­ se. Ann N Y Acad Sci 2006;1068:543-556. Go to original source...
    33. Krajcovicova A, Hlavaty T, Killinger Z, Miznerova E, Toth J, Letkovsky J, Nevidanska M, Cierny D, Koller T, Zelinkova Z, Huorka M, Payer J. Combination therapy with an immunomodulator and anti-TNF agent improves bone mineral density in IBD patients. J Crohns Colitis 2014;12:1693-1701. Go to original source...
    34. Bartl R, Frisch B. Osteoporosis, Diagnosis, prevention, therapy, 2. vydanie, Springer-Verlag 2009, Berlin, Heidelberg.
    35. Odborné usmernenie Ministerstva zdravotníctva Slovenskej republiky pre dia­ gnostiku a liečbu osteoporózy. Vestník Ministerstva zdravotníctva SR, ročník 54, odsek 24, 1. 3. 2006.
    36. SMOS pracovní skupina. Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy II. Osteologický bulletin 2007;12(1):24-33.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.